Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Allogeneic Bone Marrow Transplantation for Hematologic Malignancies: A Treatment Approach Based on Risk of Relapse and Toxicity

NCT00005797 is registered in ClinicalTrials.gov with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor.

NCT NCT00005797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00005797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Allogeneic Bone Marrow Transplantation for Hematologic Malignancies: A Treatment Approach Based on Risk of Relapse and Toxicity
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Phase
Phase 2
Overall status
Completed
Start date
March 31, 1993
Completion date
July 31, 2007
Enrollment
125 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloproliferative disorders, leukemia, multiple myeloma and malignant plasma cell neoplasms, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms